Andrew Weickhardt, MBBS(Hons), FRACP, DMedSc, Olivia Newton John Cancer Centre, Austin Hospital, Heidelberg, Australia, discusses the evolution of the treatment landscape for muscle invasive bladder cancer (MIBC), highlighting neoadjuvant immunotherapies. Prof. Weickhardt believes that immunotherapies will offer MIBC patients improved treatment and downstaging prior to cystectomy, as well as potentially offering synergistic benefits with immunotherapy and radiotherapy combination regimens. He also outlines the potential discovery and role of biomarkers in MIBC treatment. This interview took place during the 2021 Genitourinary Cancers Symposium.
Andrew Weickhardt, MBBS(Hons), FRCAO, DMedSc, has received research funding from Merck and has appeared on the Merck advisory board.